Showing results (421-430 of 538) with videos related to
Sort By:
Pageof 54
European Journal of Pharmacology|January 5, 2002
Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cellsLars Edvinsson, Rikard Alm, Duncan Shaw, et al.Journal of Molecular and Cellular Cardiology|February 2, 2016
New insights on pyrimidine signalling within the arterial vasculature - Different roles for P2Y2 and P2Y6 receptors in large and small coronary arteries of the mouseKristian Agmund Haanes, Stine Spray, Susanne Syberg, et al.Mayo Clinic Proceedings|September 24, 2005
Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trialStephen D Silberstein, Stuart R Stark, Sylvia M Lucas, et al.Headache|November 20, 2018
The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of TreatmentStephen D Silberstein, Alan M Rapoport, Pippa S Loupe, et al.Headache|April 8, 2017
Insights into the Functional Anatomy Behind the PREEMPT Injection Paradigm: Guidance on Achieving Optimal OutcomesAndrew M Blumenfeld, Stephen D Silberstein, David W Dodick, et al.Cephalalgia : an International Journal of Headache|April 20, 2021
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and IISusan Hutchinson, Stephen D Silberstein, Andrew M Blumenfeld, et al.Pain and Therapy|October 7, 2020
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT AnalysisHans-Christoph Diener, David W Dodick, Richard B Lipton, et al.Headache|October 17, 2017
AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical TrialRichard B Lipton, James S McGinley, Kenneth J Shulman, et al.Cephalalgia : an International Journal of Headache|May 22, 2019
Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT dataDavid W Dodick, Stephen D Silberstein, Richard B Lipton, et al.Pain and Therapy|October 7, 2020
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic MigraineStephen D Silberstein, Hans-Christoph Diener, David W Dodick, et al.Pageof 54